Mayerly Prada Rico1, Jaime Fernández Sarmiento2, Ana María Rojas Velasquez3, Luz Stella González Chaparro1, Ricardo Gastelbondo Amaya1, Hernando Mulett Hoyos4, Daniel Tibaduiza4, Ana Maria Quintero Gómez1. 1. Division of Pediatric Nephrology, Department of Pediatrics, Fundación Cardioinfantil IC, Instituto de Cardiologia, Bogota, Cundinamarca, Colombia. 2. Division of Pediatric Critical Care, Department of Pediatrics, Fundación Cardio-infantil IC, Universidad de la Sabana, Campus Universitario del Puente del Común, Km 7 Autopista Norte de Bogota, Chía, Cundinamarca, Colombia. JaimeFe@unisabana.edu.co. 3. Division of Pediatric Gastroenterology, Pediatric Gastroenterology, Hepatology and Nutrition Unit, GASTRONUTRIPED, Bogota, Cundinamarca, Colombia. 4. Division of Pediatric Critical Care, Department of Pediatrics, Fundación Cardio-infantil IC, Universidad de la Sabana, Campus Universitario del Puente del Común, Km 7 Autopista Norte de Bogota, Chía, Cundinamarca, Colombia.
Abstract
BACKGROUND: Anticoagulation of the continuous renal replacement therapy (CRRT) circuit is an important technical aspect of this medical procedure. Most studies evaluating the efficacy and safety of citrate use have been carried out in adults, and little evidence is available for the pediatric patient population. The aim of this study was to compare regional citrate anticoagulation versus systemic heparin anticoagulation in terms of the lifetime of hemofilters in a pediatric population receiving CRRT at a pediatric center in Bogota, Colombia. METHODS: This was an analytical, observational, retrospective cohort study in which we assessed the survival of 150 hemofilters (citrate group 80 hemofilters, heparin group 70 hemofilters) used in a total of 3442 hours of CCRT (citrate group 2248 h, heparin group 1194 h). Hemofilter survival was estimated beginning at placement and continuing until filter replacement due to clotting or high trans-membrane pressures. RESULTS: Hemofilter survival was higher in the citrate group than in the heparin group (72 vs. 18 h; p <0.0001). Bivariate analysis showed that the hemofilter coagulation risk was significantly increased when heparin was used, regardless of hemofilter size and pump flow (hazard ratio 3.70, standard error 0.82, 95% confidence interval 2.39-5.72; p <0.00001). CONCLUSIONS: Regional citrate anticoagulation could be more effective than heparin systemic anticoagulation in terms of prolonging the hemofilter lifetime in patients with acute renal injury who require CRRT.
BACKGROUND: Anticoagulation of the continuous renal replacement therapy (CRRT) circuit is an important technical aspect of this medical procedure. Most studies evaluating the efficacy and safety of citrate use have been carried out in adults, and little evidence is available for the pediatric patient population. The aim of this study was to compare regional citrate anticoagulation versus systemic heparin anticoagulation in terms of the lifetime of hemofilters in a pediatric population receiving CRRT at a pediatric center in Bogota, Colombia. METHODS: This was an analytical, observational, retrospective cohort study in which we assessed the survival of 150 hemofilters (citrate group 80 hemofilters, heparin group 70 hemofilters) used in a total of 3442 hours of CCRT (citrate group 2248 h, heparin group 1194 h). Hemofilter survival was estimated beginning at placement and continuing until filter replacement due to clotting or high trans-membrane pressures. RESULTS: Hemofilter survival was higher in the citrate group than in the heparin group (72 vs. 18 h; p <0.0001). Bivariate analysis showed that the hemofilter coagulation risk was significantly increased when heparin was used, regardless of hemofilter size and pump flow (hazard ratio 3.70, standard error 0.82, 95% confidence interval 2.39-5.72; p <0.00001). CONCLUSIONS: Regional citrate anticoagulation could be more effective than heparin systemic anticoagulation in terms of prolonging the hemofilter lifetime in patients with acute renal injury who require CRRT.
Authors: Martin Kreuzer; Klaus-Eugen Bonzel; Rainer Büscher; Gisela Offner; Jochen H H Ehrich; Lars Pape Journal: Nephrol Dial Transplant Date: 2010-04-26 Impact factor: 5.992
Authors: Jordan M Symons; Patrick D Brophy; Melissa J Gregory; Nancy McAfee; Michael J G Somers; Timothy E Bunchman; Stuart L Goldstein Journal: Am J Kidney Dis Date: 2003-05 Impact factor: 8.860
Authors: Jordan M Symons; Annabelle N Chua; Michael J G Somers; Michelle A Baum; Timothy E Bunchman; Mark R Benfield; Patrick D Brophy; Douglas Blowey; James D Fortenberry; Deepa Chand; Francisco X Flores; Richard Hackbarth; Steven R Alexander; John Mahan; Kevin D McBryde; Stuart L Goldstein Journal: Clin J Am Soc Nephrol Date: 2007-05-18 Impact factor: 8.237
Authors: Emanuele Buccione; Stefano Bambi; Laura Rasero; Lorenzo Tofani; Tessa Piazzini; Carlo Della Pelle; Khadija El Aoufy; Zaccaria Ricci; Stefano Romagnoli; Gianluca Villa Journal: J Clin Med Date: 2022-05-31 Impact factor: 4.964
Authors: Keila Rodriguez; Poyyapakkam R Srivaths; Leyat Tal; Mary N Watson; Alyssa A Riley; Ryan W Himes; Moreshwar S Desai; Michael C Braun; Ayse Akcan Arikan Journal: PLoS One Date: 2017-08-08 Impact factor: 3.240